ATAI Life Sciences (NASDAQ:ATAI) Bolsa

ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

ATAI Life Sciences NV

<a href="https://www.statnews.com/2025/06/18/fda-approval-psychedelics-rfk-jr-trump-allies-see-opening-mdma-psilocybin-mental-health-treatment/">https://www.statnews.com/2025/06/18/fda-approval-psychedelics-rfk-jr-trump-allies-see-opening-mdma-psilocybin-mental-health-treatment/</a>
&nbsp;

Biotech

News

General

ATAI

CMPS

CYBN

DRUG

ENVB

GHRS

MNMD

SEEL

'Psychedelics Proponents Hope Trump Administration Will Foster A New Era' - STAT News

<a href="https://www.marijuanamoment.net/alaska-activists-launch-campaign-to-put-psychedelics-legalization-measure-on-2026-ballot/" title="https://www.marijuanamoment.net/alaska-activists-launch-campaign-to-put-psychedelics-legalization-measure-on-2026-ballot/">https://www.marijuanamoment.net/alaska-activists-launch-campaign-to-put-psychedelics-legalization-measure-on-2026-ballot/</a>

Reported June 17, 2025: 'Alaska Activists Launch Campaign To Put Psychedelics Legalization Measure On 2026 Ballot' - Marijuana Moment

<a href="https://www.marijuanamoment.net/texas-governor-signs-bill-to-create-ibogaine-research-consortium-aiming-to-develop-fda-approved-psychedelic-drug/" title="https://www.marijuanamoment.net/texas-governor-signs-bill-to-create-ibogaine-research-consortium-aiming-to-develop-fda-approved-psychedelic-drug/">https://www.marijuanamoment.net/texas-governor-signs-bill-to-create-ibogaine-research-consortium-aiming-to-develop-fda-approved-psychedelic-drug/</a>

Politics

PSIL

'Texas Governor Signs Bill To Create Ibogaine Research Consortium, Aiming To Develop FDA-Approved Psychedelic Drug' - Marijuana Moment

<a href="https://www.marijuanamoment.net/colorado-governor-says-bill-he-signed-allowing-psychedelic-convictions-to-be-pardoned-marks-a-step-towards-a-fairer-future/" title="https://www.marijuanamoment.net/colorado-governor-says-bill-he-signed-allowing-psychedelic-convictions-to-be-pardoned-marks-a-step-towards-a-fairer-future/">https://www.marijuanamoment.net/colorado-governor-says-bill-he-signed-allowing-psychedelic-convictions-to-be-pardoned-marks-a-step-towards-a-fairer-future/</a>

"Colorado Governor Says Bill He Signed Allowing Psychedelic Convictions To Be Pardoned Marks A Step 'Towards A Fairer Future'" - Marijuana Moment

<a href="https://www.marijuanamoment.net/doctor-seeking-to-reschedule-psilocybin-to-treat-dying-patients-demands-dea-update-after-agency-agreed-to-initiate-federal-review/" title="https://www.marijuanamoment.net/doctor-seeking-to-reschedule-psilocybin-to-treat-dying-patients-demands-dea-update-after-agency-agreed-to-initiate-federal-review/">https://www.marijuanamoment.net/doctor-seeking-to-reschedule-psilocybin-to-treat-dying-patients-demands-dea-update-after-agency-agreed-to-initiate-federal-review/</a>

REUN

'Doctor Seeking To Reschedule Psilocybin To Treat Dying Patients Demands DEA Update After Agency Agreed To Initiate Federal Review' - Marijuana Moment

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/crwd/earnings">reported first-quarter results.</a>
CrowdStrike posted better-than-expected earnings for the first quarter and also raised its full-year guidance. However, the company said it expects second-quarter revenue to be between $1.145 billion and $1.152 billion versus estimates of $1.23 billion. The company anticipates second-quarter adjusted earnings of 82 cents to 84 cents per share versus estimates of 92 cents per share.
CrowdStrike shares dipped 7% to $454.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares dipped 8.4% to $17.40 in today's pre-market trading after the company reported first-quarter results.</li>
<li>Outset Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) declined 6.8% to $18.09 in pre-market trading. Outset Medical named Renee Gaeta as CFO, effective immediately.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) declined 5.5% to $59.01 in pre-market trading. Merus priced $300 million public offering of 5,263,158 common shares at $57 per share.</li>
<li>Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares declined 4.3% to $29.00 in pre-market trading.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 3.4% to $2.27 in pre-market trading after declining more than 5% on Tuesday.</li>
<li>Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) fell 2.7% to $52.06 in pre-market trading after gaining around 4% on Tuesday.</li>
</ul>
Now Read This:<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen"> </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASAN

CRWD

DOCS

MRUS

QDEL

CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

atai Life Sciences shares are trading higher after the company announced it will merge with Beckley Psytech through a share combination agreement.

<ul>
<li>Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic</li>
<li>Combined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizations</li>
<li>Topline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S.</li>
<li>The all-share transaction is expected to close in the second half of 2025</li>
<li>Concurrent $30.0M private placement by Ferring Ventures S.A. and Adage Capital Partners LP</li>
</ul>

atai And Beckley Merger Advances Strategic Vision For Psychedelic Drug Development With Deep CNS Expertise

Matthew Zorn, an attorney known for suing the federal government over <a href="https://www.benzinga.com/cannabis">cannabis and psychedelics policy</a>, is now joining it.
Zorn has been appointed Deputy General Counsel at the U.S. Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr., with a focus on psychedelics policy, according to two sources cited by <a class="" href="https://www.marijuanamoment.net/lawyer-who-sued-federal-health-agency-to-release-marijuana-documents-now-works-there-with-focus-on-psychedelics/">Marijuana Moment's Kyle Jaeger</a>. The outlet also reported that Zorn is being referred to internally as the department's "psychedelics czar." The hiring was further confirmed by <a href="https://x.com/natsfert/status/1926039985607602501">Politico reporter Natalie Fertig</a>, who also cited two sources familiar with the matter.
<h3 class="wp-block-heading">Why This Matters</h3>
Zorn's legal work has made headlines in recent years for helping push forward federal drug policy reform. He successfully sued HHS to release its 2023 scientific review recommending the reclassification of marijuana from Schedule I to Schedule III, a pivotal moment in the current rescheduling effort.
He has also represented physicians and terminal patients in litigation against the Drug Enforcement Administration (DEA), seeking federal permission to access psilocybin therapy under Right to Try laws. While courts have thus far sided with the DEA in that case, the litigation helped elevate national awareness of the issue.
Zorn's transition from courtroom adversary to federal policymaker is significant, especially at a time when top officials in the Trump administration are signaling growing support for psychedelics research, particularly for veterans facing PTSD and traumatic brain injury.
According to Marijuana Moment, the new administration has made psychedelic-assisted therapy a clear priority:
<ul class="wp-block-list">
<li>The FDA recently stated that exploring the therapeutic potential of psychedelics such as psilocybin and ibogaine is a "top priority."</li>
<li>VA Secretary Doug Collins said during a congressional hearing that his agency is seeing "positive outcomes" from psychedelic therapy studies, and is exploring the use of vouchers for veterans to access treatment outside the VA system.</li>
<li>RFK Jr. himself has previously called for legalizing psychedelics in therapeutic settings and using tax revenue to fund recovery programs.</li>
</ul>
<h3 class="wp-block-heading">Tuesday Watchlist: Psychedelics Stocks And ETFs</h3>
With markets closed on Monday for Memorial Day, investors will be watching Tuesday's trading session for potential movement in psychedelics-linked equities following this regulatory development.
Here are key stocks and ETFs to watch:
<ul class="wp-block-list">
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>)</li>
<li>MindMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>)</li>
<li>Cybin Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>)</li>
<li>Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>)</li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>)</li>
<li>The AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>)</li>
</ul>
<h3 class="wp-block-heading">What's Next?</h3>
While Zorn's new role does not automatically translate into regulatory change, it represents a clear shift: someone with a history of challenging government secrecy and opposing agency decisions is now in a position to help steer policy from within.
His appointment may bolster investor confidence in the long-term legitimacy of psychedelic-assisted therapy, particularly as the Trump administration continues to frame these treatments as potential lifelines for military veterans and trauma survivors.
Benzinga will continue monitoring regulatory updates, litigation outcomes and biotech developments in the psychedelic space.
Photo: Shutterstock

Cannabis

Psychedelics

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

ATAI Life Sciences shares are trading higher after the company announced topline data from part 2 of its Phase 2a study of BPL-003.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target

Atai Life Sciences Announces Topline Data From Part 2 Of Beckley Psytech's Phase 2a Study Of BPL-003 In Combination With SSRIs For Treatment-Resistant Depression

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 11.76 percent increase over losses of $(0.17) per share from the same period last year. The company reported $1.55 million in sales this quarter.

Earnings

Earnings Beats

ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M

atai Life Sciences Doses First Patient Dosed In Phase 2 Study Of EMP-01 For Social Anxiety Disorder; Topline Data anticipate In Q1 Of 2026

https://www.marijuanamoment.net/texas-lawmakers-take-up-bills-to-expedite-access-to-psychedelic-therapy/#:~:text=A%20Texas%20House%20committee%20took,and%20Drug%20Administration%20(FDA).

CMND

MIRA

Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 100 percent decrease over losses of $(0.12) per share from the same period last year.

Earnings Misses

ATAI Life Sciences Q4 EPS $(0.24) Misses $(0.15) Estimate

<a href="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low" title="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low">https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low</a>

Legal

'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment

atai Life Sciences Doses First Patient In Elumina Phase 2 Trial Of VLS-01 For Treatment-Resistant Depression

Atai Life Sciences Announced The Completion Of Patient Enrollment In The Eight-week, Double-blind, Core Stage Of The Global Phase 2B Clinical Trial Evaluating Bpl-003 (Mebufotenin Benzoate) In Patients With Treatment-resistant Depression (TRD)

Press Releases

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences to Participate in Upcoming Investor Conferences

Financing

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

BPMC

ICAD

LNSR

STRM

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Cronos Group

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

Maze Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nuvation Bio

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

HC Wainwright & Co.

Canaccord Genuity

Maxim Group

EF Hutton

Credit Suisse

Screenshot 2024-05-21 at 6.46.56 PM

SILO

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

ATAI Life Sciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL